C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics (Nasdaq: CCCC) approved an inducement grant of non-qualified stock options to purchase 85,480 shares of common stock for one new employee, effective May 18, 2026.

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) approved an inducement grant of non-qualified stock options to purchase 85,480 shares of common stock for one new employee, effective May 18, 2026.

The options’ exercise price equals the closing stock price on the grant date and vest over four years, subject to continued employment.

Argus May 19 session

-3.42% close to close Open Argus

Details

News Market Reaction – CCCC

In the May 19 session, CCCC declined 3.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine inducement grant of 85,480 non-qualified stock options under Nas...

Analysis

This announcement details a routine inducement grant of 85,480 non-qualified stock options under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years with a 25% first-year cliff and 36 monthly installments thereafter. It follows similar hiring-related equity actions seen in March 2026 and sits alongside larger strategic developments such as clinical progress and a Roche collaboration. Investors may monitor how ongoing equity compensation interacts with the existing $400,000,000 shelf capacity and overall share count over time.

Key Figures

Inducement option size: 85,480 shares Grant Date: May 18, 2026 Vesting period: 4 years +2 more

Inducement option size

85,480 shares

Non-qualified stock options to one new employee under inducement grant

Grant Date

May 18, 2026

Date of non-qualified stock option inducement grant

Vesting period

4 years

Inducement grant vests over four-year period

Initial vesting tranche

25%

25% of shares vest on first anniversary of start date

Remaining installments

36 monthly installments

Remainder vests in 36 equal monthly installments after first year

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 2026 earnings

   24h Move

   +0.0%

   Quarterly results with modestly lower revenue and extended cash runway.

2. Apr 09

   Roche collaboration

   24h Move

   -2.4%

   Expanded Roche DAC deal with $20M upfront and >$1B milestones.

3. Mar 25

   Clinical trial update

   24h Move

   +7.6%

   First patient dosed in Phase 1b cemsidomide plus elranatamab trial.

4. Mar 09

   Inducement grant

   24h Move

   -13.1%

   Inducement non-qualified stock option grant of 85,480 shares to one hire.

5. Feb 26

   FY 2025 earnings

   24h Move

   +0.4%

   Year-end results, cash runway to end of 2028 and financing update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"approved the grant of non-qualified stock options to purchase 85,480 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"Inducement Grant was granted as a material inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Leah Gibson
Vice President, Investor Relations & Communications
LGibson@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did C4 Therapeutics (NASDAQ: CCCC) announce on May 18, 2026 regarding an inducement grant?

C4 Therapeutics announced a non-qualified stock option inducement grant for a new employee. According to C4 Therapeutics, the award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to this individual entering employment with the company.

How many C4 Therapeutics (CCCC) stock options were granted in the May 18, 2026 inducement award?

The inducement grant consists of options to purchase 85,480 C4 Therapeutics common shares. According to C4 Therapeutics, these non-qualified stock options were approved by independent directors on the Organization, Leadership and Compensation Committee as part of the new hire’s compensation package.

What is the exercise price of the May 18, 2026 C4 Therapeutics (CCCC) inducement stock options?

The inducement options have an exercise price equal to C4 Therapeutics’ closing stock price on May 18, 2026. According to C4 Therapeutics, this pricing aligns the new employee’s equity award directly with the market value on the grant date.

How do the C4 Therapeutics (CCCC) inducement stock options vest for the new employee?

The inducement grant vests over four years, starting from the employee’s hire date. According to C4 Therapeutics, 25% vests on the first anniversary, with the remaining shares vesting in thirty-six equal monthly installments, contingent on continued employment.

Why did C4 Therapeutics (CCCC) use Nasdaq Listing Rule 5635(c)(4) for this stock option grant?

C4 Therapeutics used Nasdaq Listing Rule 5635(c)(4) to grant options as a material inducement to employment. According to C4 Therapeutics, this rule allows equity awards for new hires without prior shareholder approval when they serve as a key hiring incentive.